Review

. 2018 Oct;18(10):e295-e311.

doi: 10.1016/S1473-3099(18)30292-5. Epub 2018 Jun 18.

The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates

Natalie I Mazur¹, Deborah Higgins², Marta C Nunes³, José A Melero⁴, Annefleur C Langedijk⁵, Nicole Horsley⁶, Ursula J Buchholz⁷, Peter J Openshaw⁸, Jason S McLellan⁹, Janet A Englund¹⁰, Asuncion Mejias¹¹, Ruth A Karron¹², Eric Af Simões¹³, Ivana Knezevic¹⁴, Octavio Ramilo¹⁵, Pedro A Piedra¹⁶, Helen Y Chu¹⁷, Ann R Falsey¹⁸, Harish Nair¹⁹, Leyla Kragten-Tabatabaie²⁰, Anne Greenough²¹, Eugenio Baraldi²², Nikolaos G Papadopoulos²³, Johan Vekemans²⁴, Fernando P Polack²⁵, Mair Powell²⁶, Ashish Satav²⁷, Edward E Walsh²⁸, Renato T Stein²⁹, Barney S Graham³⁰, Louis J Bont³¹; Respiratory Syncytial Virus Network (ReSViNET) Foundation

Affiliations

¹ Laboratory of Translational Immunology, University Medical Centre Utrecht, Utrecht, Netherlands; Department of Paediatrics, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, Netherlands.
² Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA.
³ Medical Research Council: Respiratory and Meningeal Pathogens Research Unit and Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, University of the Witwatersrand, Johannesburg, South Africa; Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands.
⁴ Centro Nacional de Microbiología and CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III Majadahonda, Madrid, Spain.
⁵ Department of Paediatrics, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, Netherlands.
⁶ Department of Biology, University of Washington, Seattle, WA, USA.
⁷ Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
⁸ National Heart and Lung Institute, Faculty of Medicine, Imperial College, London, UK.
⁹ Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
¹⁰ Department of Pediatrics, University of Washington, Seattle, WA, USA; Seattle Children's Research Institute, Seattle, WA, USA.
¹¹ Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands; Department of Pediatrics, Division of Infectious Diseases, Center for Vaccines and Immunity at Nationwide Children's Hospital, The Ohio State University, Columbus, OH, USA; Departamento de Farmacología y Pediatria, Facultad de Medicina, Universidad de Malaga, Malaga, Spain.
¹² Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
¹³ Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA; Department of Epidemiology Center for Global Health, Colorado School of Public Health, Aurora, CO, USA.
¹⁴ Norms and Standards for Biologicals, Department of Essential Medicines and Health Products, World Health Organization, Geneva, Switzerland.
¹⁵ Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands; Department of Pediatrics, Division of Infectious Diseases, Center for Vaccines and Immunity at Nationwide Children's Hospital, The Ohio State University, Columbus, OH, USA.
¹⁶ Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA; Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA; Department of Molecular Virology and Microbiology, and Pediatrics, Baylor College of Medicine, Houston, TX, USA.
¹⁷ Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands.
¹⁸ Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands; Department of Medicine, University of Rochester and Rochester General Hospital, Rochester, NY, USA.
¹⁹ Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK.
²⁰ Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands; Julius Clinical, Zeist, Netherlands.
²¹ Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands; MRC-Asthma UK Centre in Allergic Mechanisms of Asthma, School of Life Course Sciences, King's College London, London, UK.
²² Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands; Women's and Children's Health Department, University of Padova, Padova, Italy.
²³ Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands; Allergy Department, 2nd Paediatric Clinic, National Kapodistrian University of Athens, Athens, Greece; Division of Infection, Immunity & Respiratory Medicine, University of Manchester, Manchester, UK.
²⁴ Initiative for Vaccine Research, World Health Organization, Geneva, Switzerland.
²⁵ Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands; Fundacion INFANT, Buenos Aires, Argentina.
²⁶ Licensing Division, Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK.
²⁷ Mahatma Gandhi Tribal Hospital, Karmagram, Utavali, Tahsil, Dharni, India.
²⁸ Department of Medicine, University of Rochester and Rochester General Hospital, Rochester, NY, USA.
²⁹ Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands; Pontificia Universidade Católica RGS (PUCRS), Porto Alegre, Brazil.
³⁰ Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
³¹ Laboratory of Translational Immunology, University Medical Centre Utrecht, Utrecht, Netherlands; Department of Paediatrics, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, Netherlands; Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands. Electronic address: l.bont@umcutrecht.nl.

PMID: 29914800
DOI: 10.1016/S1473-3099(18)30292-5

Free article

Review

The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates

Natalie I Mazur et al. Lancet Infect Dis. 2018 Oct.

Free article

. 2018 Oct;18(10):e295-e311.

doi: 10.1016/S1473-3099(18)30292-5. Epub 2018 Jun 18.

Authors

Affiliations

¹ Laboratory of Translational Immunology, University Medical Centre Utrecht, Utrecht, Netherlands; Department of Paediatrics, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, Netherlands.
² Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA.
³ Medical Research Council: Respiratory and Meningeal Pathogens Research Unit and Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, University of the Witwatersrand, Johannesburg, South Africa; Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands.
⁴ Centro Nacional de Microbiología and CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III Majadahonda, Madrid, Spain.
⁵ Department of Paediatrics, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, Netherlands.
⁶ Department of Biology, University of Washington, Seattle, WA, USA.
⁷ Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
⁸ National Heart and Lung Institute, Faculty of Medicine, Imperial College, London, UK.
⁹ Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
¹⁰ Department of Pediatrics, University of Washington, Seattle, WA, USA; Seattle Children's Research Institute, Seattle, WA, USA.
¹¹ Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands; Department of Pediatrics, Division of Infectious Diseases, Center for Vaccines and Immunity at Nationwide Children's Hospital, The Ohio State University, Columbus, OH, USA; Departamento de Farmacología y Pediatria, Facultad de Medicina, Universidad de Malaga, Malaga, Spain.
¹² Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
¹³ Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA; Department of Epidemiology Center for Global Health, Colorado School of Public Health, Aurora, CO, USA.
¹⁴ Norms and Standards for Biologicals, Department of Essential Medicines and Health Products, World Health Organization, Geneva, Switzerland.
¹⁵ Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands; Department of Pediatrics, Division of Infectious Diseases, Center for Vaccines and Immunity at Nationwide Children's Hospital, The Ohio State University, Columbus, OH, USA.
¹⁶ Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA; Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA; Department of Molecular Virology and Microbiology, and Pediatrics, Baylor College of Medicine, Houston, TX, USA.
¹⁷ Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands.
¹⁸ Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands; Department of Medicine, University of Rochester and Rochester General Hospital, Rochester, NY, USA.
¹⁹ Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK.
²⁰ Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands; Julius Clinical, Zeist, Netherlands.
²¹ Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands; MRC-Asthma UK Centre in Allergic Mechanisms of Asthma, School of Life Course Sciences, King's College London, London, UK.
²² Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands; Women's and Children's Health Department, University of Padova, Padova, Italy.
²³ Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands; Allergy Department, 2nd Paediatric Clinic, National Kapodistrian University of Athens, Athens, Greece; Division of Infection, Immunity & Respiratory Medicine, University of Manchester, Manchester, UK.
²⁴ Initiative for Vaccine Research, World Health Organization, Geneva, Switzerland.
²⁵ Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands; Fundacion INFANT, Buenos Aires, Argentina.
²⁶ Licensing Division, Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK.
²⁷ Mahatma Gandhi Tribal Hospital, Karmagram, Utavali, Tahsil, Dharni, India.
²⁸ Department of Medicine, University of Rochester and Rochester General Hospital, Rochester, NY, USA.
²⁹ Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands; Pontificia Universidade Católica RGS (PUCRS), Porto Alegre, Brazil.
³⁰ Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
³¹ Laboratory of Translational Immunology, University Medical Centre Utrecht, Utrecht, Netherlands; Department of Paediatrics, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, Netherlands; Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands. Electronic address: l.bont@umcutrecht.nl.

PMID: 29914800
DOI: 10.1016/S1473-3099(18)30292-5

Erratum in

Corrections.
[No authors listed] [No authors listed] Lancet Infect Dis. 2018 Sep;18(9):941. doi: 10.1016/S1473-3099(18)30481-X. Epub 2018 Jul 25. Lancet Infect Dis. 2018. PMID: 30056099 No abstract available.

Abstract

The global burden of disease caused by respiratory syncytial virus (RSV) is increasingly recognised, not only in infants, but also in older adults (aged ≥65 years). Advances in knowledge of the structural biology of the RSV surface fusion glycoprotein have revolutionised RSV vaccine development by providing a new target for preventive interventions. The RSV vaccine landscape has rapidly expanded to include 19 vaccine candidates and monoclonal antibodies (mAbs) in clinical trials, reflecting the urgency of reducing this global health problem and hence the prioritisation of RSV vaccine development. The candidates include mAbs and vaccines using four approaches: (1) particle-based, (2) live-attenuated or chimeric, (3) subunit, (4) vector-based. Late-phase RSV vaccine trial failures highlight gaps in knowledge regarding immunological protection and provide lessons for future development. In this Review, we highlight promising new approaches for RSV vaccine design and provide a comprehensive overview of RSV vaccine candidates and mAbs in clinical development to prevent one of the most common and severe infectious diseases in young children and older adults worldwide.

PubMed Disclaimer

Cited by

Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life.
Hosman T, van Heesbeen R, Bastian AR, Hu W, Comeaux C, Ligtenberg N, van Montfort B, Callendret B, Heijnen E. Hosman T, et al. Hum Vaccin Immunother. 2024 Dec 31;20(1):2344970. doi: 10.1080/21645515.2024.2344970. Epub 2024 May 23. Hum Vaccin Immunother. 2024. PMID: 38783590 Free PMC article. Clinical Trial.
Adjuvant-dependent impact of inactivated SARS-CoV-2 vaccines during heterologous infection by a SARS-related coronavirus.
Dillard JA, Taft-Benz SA, Knight AC, Anderson EJ, Pressey KD, Parotti B, Martinez SA, Diaz JL, Sarkar S, Madden EA, De la Cruz G, Adams LE, Dinnon KH 3rd, Leist SR, Martinez DR, Schäfer A, Powers JM, Yount BL Jr, Castillo IN, Morales NL, Burdick J, Evangelista MKD, Ralph LM, Pankow NC, Linnertz CL, Lakshmanane P, Montgomery SA, Ferris MT, Baric RS, Baxter VK, Heise MT. Dillard JA, et al. Nat Commun. 2024 May 3;15(1):3738. doi: 10.1038/s41467-024-47450-x. Nat Commun. 2024. PMID: 38702297 Free PMC article.
Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes.
Phijffer EW, de Bruin O, Ahmadizar F, Bont LJ, Van der Maas NA, Sturkenboom MC, Wildenbeest JG, Bloemenkamp KW. Phijffer EW, et al. Cochrane Database Syst Rev. 2024 May 2;5(5):CD015134. doi: 10.1002/14651858.CD015134.pub2. Cochrane Database Syst Rev. 2024. PMID: 38695784 Review.
Melatonin suppresses TLR4-mediated RSV infection in the central nervous cells by inhibiting NLRP3 inflammasome formation and autophagy.
Huang Y, Jiang C, Liu X, Tang W, Gui H, Sun T, Xu D, He M, Han M, Qiu H, Chen M, Huang S. Huang Y, et al. J Cell Mol Med. 2024 May;28(9):e18338. doi: 10.1111/jcmm.18338. J Cell Mol Med. 2024. PMID: 38683122 Free PMC article.
Maternal awareness, acceptability and willingness towards respiratory syncytial virus (RSV) vaccination during pregnancy in Ireland.
McCormack S, Thompson C, Nolan M, Imcha M, Dee A, Saunders J, Philip RK. McCormack S, et al. Immun Inflamm Dis. 2024 Apr;12(4):e1257. doi: 10.1002/iid3.1257. Immun Inflamm Dis. 2024. PMID: 38661110 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Grants and funding

001/WHO_/World Health Organization/International

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Spiral, Imperial College Digital Repository
Other Literature Sources
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates

Affiliations

The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates

Authors

Affiliations

Erratum in

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Erratum in

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical